scholarly journals Impact of Adjunctive Therapy with Chlorella Vulgaris Extract on Antioxidant Status, Pulmonary Function and Clinical Symptoms of Patients with Obstructive Pulmonary Diseases

2012 ◽  
Vol 80 (3) ◽  
pp. 719-730 ◽  
Author(s):  
Yunes Panahi
Keyword(s):  
Pulmonary Function ◽  
Chlorella Vulgaris ◽  
Adjunctive Therapy ◽  
Antioxidant Status ◽  
Clinical Symptoms ◽  
Pulmonary Diseases

scholarly journals Breathing Well Across the Lifespan: Pulmonary Aging and Geroscience-Targeted Therapies

2020 ◽  
Vol 4 (Supplement_1) ◽  
pp. 749-749
Author(s):  
Jason Sanders
Keyword(s):  
Pulmonary Fibrosis ◽  
Pulmonary Function ◽  
Pulmonary Diseases ◽  
Human Populations ◽  
Aging Research ◽  
Novel Treatments ◽  
Organ Specific ◽  
Nutrient Signaling ◽  
Telomere Biology ◽  
Increased Susceptibility

Abstract Excellent pulmonary function is one of the strongest predictors of longevity across animal models and human populations. Unfortunately, none of the major age-associated pulmonary diseases – obstructive lung disease, pulmonary fibrosis, and increased susceptibility to pneumonia – have strongly effective disease modifying therapies. There is growing evidence that normal age-associated decline in pulmonary function and major age-associated pulmonary diseases are linked to the hallmarks of aging including senescence, nutrient signaling dysregulation, mitochondrial dysfunction, and telomere disorders. This presents opportunities for collaboration between gerontologists and pulmonologists to unravel age-associated developmental mechanisms and design novel treatments. In this symposium, leaders in pulmonary aging research will present novel data on links between aging and pulmonary health and geroscience-based interventions under study. Dr. Sanders will provide an overview of the scientific and clinical space and present epidemiologic associations between aging biomarkers, early pulmonary fibrosis, and mortality. Dr. Le Saux will discuss senescence and specifically how eicosanoid biology may explain organ-specific patterns of senescence-associated fibrosis. Dr. Thannickal will discuss age-associated perturbations in metabolism and mitochondrial function and targeting these pathways to improve lung function and treat pulmonary diseases. Dr. Newton will discuss mechanisms and clinical applications of telomere biology to pulmonary aging. Symposium attendees will (1) be poised to generate collaborations between gerontologists and pulmonologists to address existing knowledge gaps in mechanisms of pulmonary aging, and (2) develop a better understanding of translational opportunities to design geroscience-based diagnostics and therapeutics to improve pulmonary health with aging.

scholarly journals Arginine Adjunctive Therapy in Active Tuberculosis

2015 ◽  
Vol 2015 ◽  
pp. 1-5 ◽  
Author(s):  
Aliasghar Farazi ◽  
Omid Shafaat ◽  
Masoomeh Sofian ◽  
Manijeh Kahbazi
Keyword(s):  
Weight Gain ◽  
Adjunctive Therapy ◽  
Clinical Symptoms ◽  
Treatment Success ◽  
Active Tuberculosis ◽  
Final Treatment ◽  
Smear Positive Pulmonary Tuberculosis ◽  
Sputum Conversion ◽  
Spss Software ◽  
Clinical Trials Registry

Background. Dietary supplementation has been used as a mechanism to augment the immune system. Adjunctive therapy with L-arginine has the potential to improve outcomes in active tuberculosis.Methods. In a randomized clinical trial 63 participants with smear-positive pulmonary tuberculosis in Markazi Province of Iran were given arginine or placebo for 4 weeks in addition to conventional chemotherapy. The final treatment success, sputum conversion, weight gain, and clinical symptoms after one and two months were considered as primary outcomes and secondary outcomes were ESR, CRP, and Hg. Data were collected and analyzed with SPSS software (ver. 18).Results. Arginine supplementation reduced constitutional symptoms (P=0.032) in patients with smear-positive TB at the end of the first month of treatment. Arginine treated patients had significantly increased BMI at the end of the first and second months of treatment (P=0.032andP=0.04) and a reduced CRP at the end of the first month of treatment (P=0.03) versus placebo group.Conclusion. Arginine is useful as an adjunctive therapy in patients with active tuberculosis, in which the effects are more likely mediated by the increased production of nitric oxide and improved constitutional symptoms and weight gain. This trial is registered with Clinical Trials Registry of Iran:IRCT201211179855N2.

Investigation of the effects of Chlorella vulgaris as an adjunctive therapy for dyslipidemia: Results of a randomized open-label clinical trial

2011 ◽  
Vol 44 (13) ◽  
pp. S338-S339
Author(s):  
Amirhossein Sahebkar ◽  
Yunes Panahi ◽  
Hamid Reza Jalalian ◽  
Bahram Pishgoo ◽  
Elaheh Mohammadi ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Chlorella Vulgaris ◽  
Adjunctive Therapy ◽  
Open Label

Investigation of the effects of Chlorella vulgaris as an adjunctive therapy for dyslipidemia: Results of a randomised open-label clinical trial

2012 ◽  
Vol 69 (1) ◽  
pp. 13-19 ◽  
Author(s):  
Yunes PANAHI ◽  
Bahram PISHGOO ◽  
Hamid R. JALALIAN ◽  
Elaheh MOHAMMADI ◽  
Hamid R. TAGHIPOUR ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Chlorella Vulgaris ◽  
Adjunctive Therapy ◽  
Open Label

scholarly journals Association of HMGB1, S100A12 and IL-17A Expression with IVIG-Resistant Kawasaki Disease and Treatment Options

2020 ◽  
Author(s):  
Deying Liu ◽  
Pan Liu ◽  
Fan Liu ◽  
Wei Yin ◽  
Yan Ding
Keyword(s):  
Kawasaki Disease ◽  
Coronary Arteries ◽  
Adjunctive Therapy ◽  
Clinical Symptoms ◽  
Treatment Options ◽  
Poor Response ◽  
Serum Levels ◽  
Laboratory Parameters ◽  
Molecular Pattern

Abstract Background: Kawasaki disease (KD) is a medium vessel vasculitis of unknown aetiology that predominantly affecting coronary arteries. The damage-associated molecular pattern molecules (DAMPs) such as HMGB1, S100A12 and IL-17A have been reported to predict poor response to IVIG. Here, we explored the the role of HMGB1, S100A12 and IL-17A in the detection of intravenous immunoglobulin (IVIG)-resistant in KD patients, and to investigate the value of different adjunctive therapy.Method: 126 KD patients and as well as age- and sex-matched 16 febrile control subjects were enrolled in our study. The fresh peripheral blood were collected from KD patients and febrile controls, analyzed the demographic or clinical data and various laboratory parameters. We also measured changes in serum levels of IL-17A and mRNA expression levels of HMGB1 and S100A12 were tested in IVIG-resistant KD patients. Further we explored the association between coronary arteries lesions and different treatment options about IVIG retreatment, methylprednisolone and infliximab for IVIG-resistant KD patients. Result: Regarding laboratory parameters, KD individuals were found to have lower levels of lymphocyte(L)%, prealbumin, CD4+, CD8+ and higher levels of WBC, neutrophil (N)%, CRP, ESR, NT-proBNP, ALT, CD4+/CD8+ (P<0.05 or P<0.01). For KD group, the 53 IVIG-resistant patients had significantly higher levels of S100A12, HMGB1, serum IL-17A, N%, CRP, NT-proBNP, TBIL, ALT, AST and lower levels of L%, PLT (P<0.05 or P<0.01) in comparison to the IVIG-responsive patients. For patients with IVIG-resistant, IVIG retreatment, methylprednisolone or infliximab were used. Methylprednisolone showed better in improving clinical symptoms and CRP than the IVIG retreatment and infliximab (P> 0.05).Conclusion: IVIG-resistant was associated with overreaction of inflammation.The levels of HMGB1,S100A12 and IL-17A suggested to be reliable predictors for IVIG-resistant in KD. In addition, the adjunctive therapy of methylprednisolone and infliximab showed more effective in relieving clinical symptoms than IVIG retreatment.

scholarly journals Association of HMGB1, S100A12 and IL-17A Expression with Immunoglobulin-Resistant in Kawasaki Disease and the Comparisons Between Different Adjunctive Therapeutic Approaches

2022 ◽  
Author(s):  
Yang Zhou ◽  
Liu Pan ◽  
You-jun Yang ◽  
Shi-yu Li ◽  
Wei Yin ◽  
...  
Keyword(s):  
Adjunctive Therapy ◽  
Clinical Symptoms ◽  
Poor Response ◽  
Serum Levels ◽  
Ivig Treatment ◽  
Control Group ◽  
Laboratory Parameters ◽  
Methyl Prednisolone ◽  
Laboratory Variables

Abstract Objective: The DAMPs such as HMGB1, S100A12 and IL-17A have been reported to predict poor response to IVIG. The aim of this study was to analyze the role of HMGB1,S100A12 and IL-17A in the detection of inflammation in KD patients with IVIG-resistant, and to investigate the value of different adjunctive therapy.Method: This study enrolled 126 patients diagnosed with KD, as well as age-matched 16 febrile control subjects. The demographic or clinical data, laboratory parameter and blood sample were collected. Various laboratory parameters as predictive factors for IVIG-resistant were calculated. And the serum levels of IL-17A and mRNA expression levels of HMGB1 and S100A12 were tested in all patients. For patients with acute KD in IVIG-resistant, we studied the levels of laboratory variables when using of IVIG retreatment, methylprednisolone, infliximab for children patients. Result: The variance of laboratory parameters between the febrile control group and KD group were analyzed. Regarding laboratory parameters, KD individuals were found to have lower levels of L%, PA, CD4+, CD8+ and higher levels of WBC, N%, CRP, ESR, NT-proBNP, ALT, CD4+/CD8+ (P<0.05 or P<0.01). For KD group, the 53 IVIG-resistant patients had significantly higher levels of blood S100A12, HMGB1, serum IL-17A levels And N%, CRP, NT-pro BNP, TBIL, ALT, AST and lower levels of L%, PLT (P<0.05 or P<0.01) in comparison to the IVIG-responsive patients. For patients with acute KD in IVIG-resistant, after initial IVIG-treatment, the adjunctive therapy of IVIG, methyl prednisolone or infliximab were used, the inflammatory symptoms and laboratory inflammatory markers were improved when treated with those drugs. Conclusion: IVIG-resistant was associated with higher levels of HMGB1, S100A12, IL-17A, CRP, NT-pro BNP, TBIL, ALT, AST and lower levels of L%, PLT before IVIG, especially when combined, were useful predictors for IVIG-resistant in KD. In addition, the adjunctive therapy of methylprednisolone and infliximab showed more effective in relief clinical symptoms than IVIG retreatment.

Sign in / Sign up

Export Citation Format

Share Document